Myriad Announces Diabetes Collaboration With Sanofi
As part of the agreement,
"We are pleased to be partnering with Sanofi and PHRI, world leaders in diabetes research, on this critical study," said
Funded by Sanofi and directed and managed by PHRI, ORIGIN is a unique, six-year landmark cardiovascular (CV) outcomes trial, that evaluated Lantus® (insulin glargine) versus standard care in over 12,500 individuals at high CV risk with pre-diabetes or early type 2 diabetes mellitus. Spanning 40 countries worldwide, it was the world's longest and largest randomized clinical trial of its type in this population.
"This biomarker project using DiscoveryMAP is a logical extension of the landmark ORIGIN study," said Dr.
This collaboration could represent up to
Myriad, the Myriad logo,
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the timing, scope, goals, completion, and anticipated outcomes of the collaboration and study to perform protein biomarker discovery on over 8,000 serum samples from patients with pre-diabetes or type 2 diabetes; the Company's belief that this collaboration will result in better care for millions of patients with diabetes; the expectation of this collaboration representing, and the Company realizing, over
CONTACT: Myriad Contacts: Investor RelationsSource:
Jim Evans, Chief Financial Officer (801) 584-1143 firstname.lastname@example.org Myriad RBM Chris Martin, Director of Communications (212) 275-2623 email@example.com Media Relations Stephanie Ashe Continuum Health Communicationssashe@continuumhealthcom.com
News Provided by Acquire Media